The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
A review of cancer immunotherapy toxicity
Open accessAbstract
Cancer immunotherapies, including checkpoint inhibitors and adoptive cell therapy, manipulate the immune system to recognize and attack cancer cells. These therapies have the potential to induce durable responses in multiple solid and hematologic malignancies and thus have transformed treatment algorithms for numerous tumor types. Cancer immunotherapies lead to unique toxicity profiles distinct from the toxicities of other cancer therapies, depending on their mechanism of action. These toxicities often require specific management, which can include steroids and immune‐modulating therapy and for which consensus guidelines have been published. This review will focus on the toxicities of checkpoint inhibitors and chimeric antigen receptor T cells, including pathophysiology, diagnosis, and management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1804980 · Cited by 4,112
Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6385 · Cited by 3,713
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Cited by
Dai, M., Liu, D., Liu, M., Zhou, F., Li, G., Chen, Z., Zhang, Z., You, H., Wu, M., Zheng, Q., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0422 · Cited by 1,589
Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms
Cani, P. D., Depommier, C., Derrien, M., Everard, A., & de Vos, W. M. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00631-9 · Cited by 1,192
Artificial intelligence for multimodal data integration in oncology
Lipkova, J., Chen, R. J., Chen, B., Lu, M. Y., Barbieri, M., Shao, D., Vaidya, A. J., Chen, C., Zhuang, L., Williamson, D. F. K., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.09.012 · Cited by 777
Exosome-based immunotherapy: a promising approach for cancer treatment
Xu, Z., Zeng, S., Gong, Z., & Yan, Y. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01278-3 · Cited by 482
Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy
Lu, Q., Kou, D., Lou, S., Ashrafizadeh, M., Aref, A. R., Canadas, I., Tian, Y., Niu, X., Wang, Y., Torabian, P., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01535-8 · Cited by 373
Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review
Kumar, A., Gautam, V., Sandhu, A., Rawat, K., Sharma, A., & Saha, L. (2023) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v15.i4.495 · Cited by 272
Zhou, C., Peng, S., Lin, A., Jiang, A., Peng, Y., Gu, T., Liu, Z., Cheng, Q., Zhang, J., & Luo, P. (2023) · eClinicalMedicine · doi:10.1016/j.eclinm.2023.101967 · Cited by 213
Current and future perspectives of PD-1/PDL-1 blockade in cancer immunotherapy
Makuku, R., Khalili, N., Razi, S., Keshavarz-Fathi, M., & Rezaei, N. (2021) · Journal of Immunology Research · doi:10.1155/2021/6661406 · Cited by 136
Harnessing big data to characterize immune-related adverse events
Jing, Y., Yang, J., Johnson, D. B., Moslehi, J. J., & Han, L. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00597-8 · Cited by 125
Extracellular vesicles remodel tumor environment for cancer immunotherapy
Yue, M., Hu, S., Sun, H., Tuo, B., Jia, B., Chen, C., Wang, W., Liu, J., Liu, Y., Sun, Z., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01898-5 · Cited by 119
Kerns, S. J., Belgur, C., Petropolis, D., Kanellias, M., Barrile, R., Sam, J., Weinzierl, T., Fauti, T., Freimoser-Grundschober, A., Eckmann, J., et al. (2021) · eLife · doi:10.7554/elife.67106 · Cited by 82
Overcoming Resistance to Drugs Targeting KRAS Mutation
Jiao, D., & Yang, S. (2020) · The Innovation · doi:10.1016/j.xinn.2020.100035 · Cited by 61
Organoid co‐culture models of the tumor microenvironment promote precision medicine
Gu, Z., Wu, Q., Shang, B., Zhang, K., & Zhang, W. (2024) · Cancer Innovation · doi:10.1002/cai2.101 · Cited by 47
Recent advances in exosome-based immunotherapy applied to cancer
Xie, J., Zheng, Z., Tuo, L., Deng, X., Tang, H., Peng, C., & Zou, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1296857 · Cited by 40
Enzyme/pH Dual-Responsive Engineered Nanoparticles for Improved Tumor Immuno-Chemotherapy
Liu, Z., Hao, X., Qian, J., Zhang, H., Bao, H., Yang, Q., Gu, W., Huang, X., & Zhang, Y. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c18348 · Cited by 24
Najmi, M., Tran, T., Witt, R. G., & Nelson, K. C. (2022) · Dermatology and Therapy · doi:10.1007/s13555-022-00810-1 · Cited by 21
Targeting tumor extracellular matrix with nanoparticles to circumvent therapeutic resistance
Ding, X., Liang, Y., Zhou, S., Wu, Y., Sałata, P., Mikolajczk-Martinez, A., Khosrawipour, V., & Zhang, Z. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113786 · Cited by 20
Xie, L., Liang, X., Xu, J., Sun, X., Liu, K., Sun, K., Li, Y., Tang, X., Li, X., Zhan, X., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-11390-4 · Cited by 14
Effects of antibiotics on the anti-tumor efficacy of immune checkpoint inhibitor therapy
Nie, F., Guo, J., Pan, J., Guo, Z., Wang, C., Yan, J., & Ma, W. (2024) · Clinical and Translational Oncology · doi:10.1007/s12094-024-03615-0 · Cited by 4
Metadata
- Authors
- Kennedy, L. B., & Salama, A. K. S.
- Venue
- CA: A Cancer Journal for Clinicians
- Publisher
- Wiley
- Published
- 2020-01-16
- Volume
- 70
- Issue
- 2
- Pages
- 86-104
- ISSN
- 0007-9235 (ISSN-L)
- 1542-4863
- OpenAlex
- W2999281781
- Cited by
- 1,364
- References
- 42
- FWCI
- 62.48
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
